Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 20, 2026 08:30 ET | Source: BioMedWire

When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech

AUSTIN, Texas, April 20, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Biotechnology is undergoing a quiet but profound transformation, one that is reshaping how investors understand value...
August 29, 2025 15:13 ET | Source: Robbins LLP

SRPT Stock Alert: Investors with Large Losses Should Contact Robbins LLP for Information About the Pending Lead Plaintiff Deadline in the Sarepta Therapeutics, Inc. Class Action

Robbins LLP is Investigating Allegations that Sarepta Therapeutics, Inc. (SRPT) Mislead Investors Regarding the Safety its ELEVIDYS Drug
August 18, 2025 17:56 ET | Source: Robbins LLP

Robbins LLP Reminds Sarepta Therapeutics, Inc. Stockholders of the Pending Lead Plaintiff Deadline in the Securities Class Action Against SRPT

Robbins LLP is Investigating Allegations that Sarepta Therapeutics, Inc. (SRPT) Mislead Investors Regarding the Safety its ELEVIDYS Drug
July 07, 2025 17:24 ET | Source: Robbins LLP

Robbins LLP Reminds Sarepta Therapeutics, Inc. Investors with Large Losses to Contact the Firm for Information About the SRPT Class Action Lawsuit

Robbins LLP is Investigating Allegations that Sarepta Therapeutics, Inc. (SRPT) Mislead Investors Regarding the Safety its ELEVIDYS Drug
July 03, 2025 19:33 ET | Source: Robbins LLP

Sarepta Therapeutics, Inc. Class Action Notice: Robbins LLP Reminds SRPT Stockholders of the Lead Plaintiff Deadline in the SRPT Class Action Lawsuit

Robbins LLP is Investigating Allegations that Sarepta Therapeutics, Inc. (SRPT) Mislead Investors Regarding the Safety its ELEVIDYS Drug
June 30, 2025 19:28 ET | Source: Robbins LLP

Shareholder Alert: Robbins LLP Informs Investors of the Sarepta Therapeutics, Inc. Class Action

Robbins LLP is Investigating Allegations that Sarepta Therapeutics, Inc. (SRPT) Mislead Investors Regarding the Safety its ELEVIDYS Drug